Bourdeaux C, Darwish A, Jamart J, Tri T T, Janssen M, Lerut J, Otte J-B, Sokal E, de Ville de Goyet J, Reding R
Pediatric Liver Transplant Program, Université Catholique de Louvain, Saint-Luc University Clinics, Brussels, Belgium.
Am J Transplant. 2007 Feb;7(2):440-7. doi: 10.1111/j.1600-6143.2006.01626.x. Epub 2006 Dec 6.
Timely access to a living donor (LD) reduced pretransplant mortality in pediatric liver transplantation (LT). We hypothesized that this strategy may provide better posttransplant outcome. Between July 1993 and April 2002, 235 children received a primary LT from a LD (n = 100) or a deceased donor (DD) (n = 135). Demographic, surgical and immunological variables were compared, and respective impact on posttransplant complications was studied using a multivariate analysis. Five-year patient survival rates were 92% and 85% for groups LD and DD, respectively (p = 0.181), the corresponding graft survival rates being 89% and 77% (p = 0.033). At multivariate analysis: (1) type of donor (DD) was correlated with higher rate of artery thrombosis (p < 0.012); (2) biliary complication rate at 5 years was 29% and 23% for groups LD and DD, respectively (p = 0.451); (3) lower acute rejection incidence could be correlated with type of donor (DD) (p = 0.001), and immunosuppressive therapy (tacrolimus) (p < 0.001). We conclude that (1) according to the multivariate analysis, LT with LD provided similar patient and graft outcome, when compared to DD; (2) a higher rate of artery thrombosis and a lower rate of rejection were observed in group DD; (3) this study confirms the efficacy of tacrolimus for immunoprophylaxis, whatever the type of organ donor is.
及时获得活体供体(LD)可降低小儿肝移植(LT)术前死亡率。我们推测这一策略可能会带来更好的移植后结局。1993年7月至2002年4月期间,235名儿童接受了来自活体供体(n = 100)或脑死亡供体(DD)(n = 135)的首次肝移植。比较了人口统计学、手术和免疫学变量,并使用多变量分析研究了它们对移植后并发症的各自影响。LD组和DD组的5年患者生存率分别为92%和85%(p = 0.181),相应的移植物生存率分别为89%和77%(p = 0.033)。多变量分析结果如下:(1)供体类型(DD)与较高的动脉血栓形成率相关(p < 0.012);(2)LD组和DD组5年时的胆道并发症发生率分别为29%和23%(p = 0.451);(3)较低的急性排斥反应发生率可能与供体类型(DD)(p = 0.001)和免疫抑制治疗(他克莫司)(p < 0.001)有关。我们得出结论:(1)根据多变量分析,与脑死亡供体相比,活体供体肝移植的患者和移植物结局相似;(2)脑死亡供体组观察到较高的动脉血栓形成率和较低的排斥反应率;(3)本研究证实了无论器官供体类型如何,他克莫司在免疫预防方面的有效性。